Elizabeth Nghiem, MD
Infectious Disease · Tustin, CANPI 1083626212
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,701 of the $9,614 with a category attached, or 80.1%. AbbVie accounts for 69.8% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $5,728 and has fallen 94.4% since, to $323 in 2025.
Across 48 payments — averaging $200.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Regeneron Healthcare Solutions, Inc.$2K
- Shionogi Inc$245
- Gilead$239
- Stryker$169
- Novo Nordisk$125
- plus $424 from 6 others
What the payments were for
- Speaking & faculty fees$7,70180%
- Travel & lodging$2362%
- Food & beverage$1,66417%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $6,711 |
| Regeneron Healthcare Solutions, Inc. | 2 | $1,701 |
| Shionogi Inc | 8 | $245 |
| Gilead | 2 | $239 |
| Stryker | 1 | $169 |
| Novo Nordisk | 1 | $125 |
| Chiesi USA, Inc. | 1 | $123 |
| Amgen | 1 | $120 |
| Melinta Therapeutics, LLC | 4 | $75 |
| Regeneron | 1 | $57 |
| Merck | 2 | $33 |
| Organogenesis Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,614 in reported general payments places this provider in the 85th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErtapenemErtapenem Sodium | 31 | $16,663 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 13 | $2,863 |
| Cefazolin Sodium | 11 | $1,227 |
| CeftriaxoneCeftriaxone Sodium | 17 | $1,111 |
| Fluconazole | 18 | $708 |
| Sodium Chloride0.9 % Sodium Chloride | 15 | $445 |
| Tobramycin Sulfate | 23 | $340 |
| Amikacin Sulfate | 12 | $195 |
| Azithromycin | 12 | $175 |
| Cephalexin | 13 | $151 |
| WaterWater For Irrigation,sterile | 11 | $107 |
| Levofloxacin | 12 | $89 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Tustin
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- James McKinnellTorrance$762K
- Jay GladsteinLos Angeles$657K
- Tulika SinghOrange$654K
- Otto YangLos Angeles$472K
- Franco FelizartaBakersfield$440K
- Shawn HasslerSan Francisco$433K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.